A Phase I Trial of Vandetanib Combined With 131I-mIBG Radiotherapy in Patients With Neuroendocrine Tumours, Advanced Phaeochromocytoma and Paraganglioma

Trial Profile

A Phase I Trial of Vandetanib Combined With 131I-mIBG Radiotherapy in Patients With Neuroendocrine Tumours, Advanced Phaeochromocytoma and Paraganglioma

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 17 Mar 2017

At a glance

  • Drugs Vandetanib (Primary) ; Iobenguane
  • Indications Paraganglioma; Phaeochromocytoma
  • Focus Adverse reactions
  • Acronyms VIBRaNT
  • Most Recent Events

    • 17 Mar 2017 This trial has been discontinued in United Kingdom.
    • 15 Dec 2015 Status changed from recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
    • 02 Dec 2014 Planned End Date changed from 1 Jan 2019 to 1 Dec 2019 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top